ArticleAmerican journal of cancer research2025
Short- and long-term efficacy of olaparib combined with chemotherapy in advanced triple-negative breast cancer.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Roles of ADP-Ribosyltransferases in Cancer.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the short- and long-term efficacy of olaparib combined with chemotherapy as adjuvant therapy in patients with advanced triple-negative breast cancer (TNBC).
methodsThis retrospective cohort study included 274 patients with advanced TNBC, divided into an observation group (olaparib + chemotherapy, n = 116) and a control group (chemotherapy alone, n = 158). Primary outcome measures included Objective Response Rate (ORR), Disease Control Rate (DCR), immune function indicators (CD3+, CD4+/CD8+ ratio, Natural Killer T cells), cytokine levels (Interferon-gamma, Interleukin-2, Interleukin-6), tumor markers [Carcinoembryonic Antigen, Carbohydrate Antigen 153, Human Epididymis Protein 4], Karnofsky Performance Status (KPS), Progression-Free Survival (PFS), Overall Survival (OS), and adverse event incidence.
resultsThe observation group showed significantly higher ORR and DCR (both P < 0.05) than the control group. Immune function and cytokine levels improved significantly in the observation group (both P < 0.05). In contrast, IL-6 levels increased significantly in the control group (P < 0.05). Tumor marker levels were lower in the observation group (all P < 0.001). KPS scores were significantly higher in the observation group at 1, 3, and 6 months post-treatment (all P < 0.05). The observation group exhibited prolonged PFS and OS (both P < 0.05).
conclusionsOlaparib combined with chemotherapy enhances short- and long-term efficacy, improves immune function, and prolongs survival in advanced TNBC without increasing treatment-related toxicity, supporting its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.